Overview

Safety and Anti-Disease Activity of Oral Tosedostat (CHR-2797) in Elderly Subjects With Refractory or Relapsed AML

Status:
Completed
Trial end date:
2011-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of tosedostat in elderly patients suffering from refractory or relapsed AML.
Phase:
Phase 2
Details
Lead Sponsor:
Chroma Therapeutics
Collaborator:
Quintiles, Inc.
Treatments:
Glycine
Tosedostat